ArticleFrontiers in immunology2026
Altered extracellular matrix remodeling accompanies decreased lncRNA HOTAIR expression in Takayasu arteritis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Takayasu arteritis (TAK) is a large-vessel vasculitis characterized by chronic vascular inflammation and extracellular matrix (ECM) remodeling. Long non-coding RNAs (lncRNAs) have emerged as epigenetic regulators of inflammatory and structural vascular processes. This study aimed to evaluate whether lncRNA HOTAIR (HOX transcript antisense RNA) expression in peripheral blood mononuclear cells (PBMCs) is associated with circulating mediators involved in ECM turnover in patients with TAK. Methods: Fifty-three patients with angiographically confirmed TAK and 53 age- and sex-matched healthy controls were recruited. HOTAIR expression in PBMCs was quantified by reverse transcription-quantitative polymerase chain reaction. Serum concentrations of matrix metalloproteinase-1 (MMP-1), MMP-2, MMP-3, MMP-9, MMP-13, tissue inhibitor of metalloproteinases-1 (TIMP-1), TIMP-3, extracellular matrix metalloproteinase inducer (EMMPRIN)/CD147, and galectin-3 were measured using enzyme-linked immunosorbent assays. Results: Compared with controls, TAK patients exhibited significantly higher serum levels of MMP-2 (2245 [1929-2646] vs. 1868 [1576-2355] pg/mL; p=0.036), TIMP-1 (2811 [2644-3216] vs. 2588 [2309-2770] pg/mL; p=0.006), and EMMPRIN/CD147 (1494 [1264-2115] vs. 1310 [1132-1655] pg/mL; p=0.035), along with a reduced MMP-9/TIMP-1 ratio (0.88 [0.61-1.28] vs. 1.18 [0.91-1.41]; p=0.006). HOTAIR expression was markedly downregulated in TAK patients (8.05 [2.52-24.54] vs. 36.09 [30.08-43.85] arbitrary units; p=0.006) and was not associated with disease activity. Notably, HOTAIR expression inversely correlated with circulating MMP-2 (Spearman's rho -0.276) and EMMPRIN/CD147 (Spearman's rho -0.280) levels. Conclusion: TAK displays a circulating proteolytic profile consistent with enhanced ECM turnover and vascular remodeling. The marked downregulation of HOTAIR supports the involvement of epigenetic mechanisms in TAK and suggests a potential association between reduced HOTAIR expression and MMP-mediated vascular injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.